

Title: Incorporating TKI Therapy into CML Management
Dates: November 23, 2015 – November 23, 2016
Locations: Online: http://www.mycmesitel.com/index.aspx?case_id=542

Learning Objectives

Upon the conclusion of this activity, the participant should be able to:

- Assess the efficacy, safety and guideline indications for various CML TKI therapy options
- Evaluate cytogenetic and molecular tests as tools to individualize patient management plans
- Describe guideline and evidenced-based data regarding CML therapy adjustments vis-à-vis time-based clinical responses

Target Audience

This activity is designed for medical oncologists, hematologists, hematologist/oncologists and oncology nurses/advanced practitioners.

Program Overview

The goal of this activity is for medical oncologists, hematologists, hematologist/oncologists and oncology nurses/advanced practitioners to better understand the current treatment options for patients with CML and how to optimize their use in different patients.

Faculty

Javier Pinilla-Ibarz, MD, PhD
Associate Member
Director of Immunotherapy
Malignant Hematology Department
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and ASiM. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Clinical and Patient Educators Association designates this enduring material for a maximum of 1.0 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

CPEA requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Commercial Support

This activity is supported by an educational grant from Bristol-Myers Squibb Company.